{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T02:03:02Z","timestamp":1772244182944,"version":"3.50.1"},"reference-count":79,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2013.0575","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T05:25:18Z","timestamp":1525238718000},"source":"Crossref","is-referenced-by-count":14,"title":["Does the Pharmaceutical Industry Influence Guidelines? Two Examples From Germany"],"prefix":"10.3238","author":[{"given":"Gisela","family":"Schott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"D\u00fcnnweber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"M\u00fchlbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilhelm","family":"Niebling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Pachl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolf-Dieter","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11437","published-online":{"date-parts":[[2013,9,2]]},"reference":[{"key":"10.3238\/arztebl.2013.0575_ref1","unstructured":"Hart D: \u00c4rztliche Leitlinien. In: Rieger H-J (ed): Lexikon des Arztrechts. 2nd edition, Heidelberg: Verlag C. F. M\u00fcller 2001."},{"key":"10.3238\/arztebl.2013.0575_ref2","doi-asserted-by":"crossref","unstructured":"Lelgemann M, Lang B, Kunz R, Antes G: Leitlinien. Was haben \u00c4rzte und Patienten davon. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2005; 48: 215\u201320.","DOI":"10.1007\/s00103-004-0982-5"},{"key":"10.3238\/arztebl.2013.0575_ref3","unstructured":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V.: AWMF online \u2013 das Portal der wissenschaftlichen Medizin: http:\/\/awmf.org\/. Last accessed on 6 November 2012."},{"key":"10.3238\/arztebl.2013.0575_ref4","doi-asserted-by":"crossref","unstructured":"Kopp I: Erstellung und Handhabung von Leitlinien aus Sicht der AWMF. MKG-Chirurg 2010; 2: 79\u201385.","DOI":"10.1007\/s12285-009-0083-4"},{"key":"10.3238\/arztebl.2013.0575_ref5","doi-asserted-by":"crossref","unstructured":"Sch\u00fcnemann H: Integrative Beurteilung der Evidenz im Gesundheitswesen: das GRADE System. Z Evid Fortbild Qual Gesundhwes 2009; 103: 261\u20138.","DOI":"10.1016\/j.zefq.2009.05.007"},{"key":"10.3238\/arztebl.2013.0575_ref6","doi-asserted-by":"crossref","unstructured":"Tricoci P, Allen JM, Kramer JM, Califf RM, Smith SC Jr.: Scientific evidence underlying the ACC\/AHA clinical practice guidelines. JAMA 2009; 301: 831\u201341.","DOI":"10.1001\/jama.2009.205"},{"key":"10.3238\/arztebl.2013.0575_ref7","doi-asserted-by":"crossref","unstructured":"Wang AT, McCoy CP, Murad MH, Montori VM: Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. BMJ 2010; 340: c1344.","DOI":"10.1136\/bmj.c1344"},{"key":"10.3238\/arztebl.2013.0575_ref8","unstructured":"Committee on Conflict of Interest in Medical Research, Education, and Practice, Institute of Medicine: Lo B, Field MJ (eds): Conflict of Interest in Medical Research, Education, and Practice. 1th edition, Washington D.C.: National Academies Press 2009."},{"key":"10.3238\/arztebl.2013.0575_ref9","doi-asserted-by":"crossref","unstructured":"Lieb K, Klemperer D, Ludwig W-D: Einleitung. In: Lieb K, Klemperer D, Ludwig WD (eds): Interessenskonflikte in der Medizin \u2013 Hintergr\u00fcnde und L\u00f6sungsm\u00f6glichkeiten. Berlin, Heidelberg, New York: Springer Medizin Verlag 2011; 3\u20139.","DOI":"10.1007\/978-3-642-19842-7_1"},{"key":"10.3238\/arztebl.2013.0575_ref10","doi-asserted-by":"crossref","unstructured":"Thompson DF: Understanding financial conflicts of interest. N Engl J Med 1993; 329: 573\u20136.","DOI":"10.1056\/NEJM199308193290812"},{"key":"10.3238\/arztebl.2013.0575_ref11","doi-asserted-by":"crossref","unstructured":"Medical Professionalism Project: Medical professionalism in the new millennium: a physicians\u2019 charter. Lancet 2002; 359: 520\u20132.","DOI":"10.1016\/S0140-6736(02)07684-5"},{"key":"10.3238\/arztebl.2013.0575_ref12","doi-asserted-by":"crossref","unstructured":"Schott G, Pachl H, Limbach U, Gundert-Remy U, Ludwig WD, Lieb K: The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials. Dtsch Arztebl Int 2010; 107: 279\u201385.","DOI":"10.3238\/arztebl.2010.0295"},{"key":"10.3238\/arztebl.2013.0575_ref13","doi-asserted-by":"crossref","unstructured":"Schott G, Pachl H, Limbach U, Gundert-Remy U, Lieb K, Ludwig WD: The financing of drug trials by pharmaceutical companies and its consequences. Part 2: a qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication. Dtsch Arztebl Int 2010; 107: 295\u2013301.","DOI":"10.3238\/arztebl.2010.0295"},{"key":"10.3238\/arztebl.2013.0575_ref14","doi-asserted-by":"crossref","unstructured":"Langer T, Conrad S, Fishman L, Gerken M, Schwarz S, Weikert B, et al.: Conflicts of interest among authors of medical guidelines: an analysis of guidelines produced by german specialist societies. Dtsch Arztebl Int 2012; 109: 836\u201342.","DOI":"10.3238\/arztebl.2012.0836"},{"key":"10.3238\/arztebl.2013.0575_ref15","doi-asserted-by":"crossref","unstructured":"Steinman MA, Bero LA, Chren MM, Landefeld CS: Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med 2006; 145: 284\u201393.","DOI":"10.7326\/0003-4819-145-4-200608150-00008"},{"key":"10.3238\/arztebl.2013.0575_ref16","doi-asserted-by":"crossref","unstructured":"Landefeld CS, Steinman MA: The Neurontin legacy \u2013 marketing through misinformation and manipulation. N Engl J Med 2009; 360: 103\u20136.","DOI":"10.1056\/NEJMp0808659"},{"key":"10.3238\/arztebl.2013.0575_ref17","doi-asserted-by":"crossref","unstructured":"Vedula SS, Bero L, Scherer RW, Dickersin K: Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med 2009; 361: 1963\u201371.","DOI":"10.1056\/NEJMsa0906126"},{"key":"10.3238\/arztebl.2013.0575_ref18","doi-asserted-by":"crossref","unstructured":"Vedula SS, Li T, Dickersin K: Differences in reporting of analyses in internal company documents versus published trial reports: comparisons in industry-sponsored trials in off-label uses of gabapentin. PLoS Med 2013; 10: e1001378.","DOI":"10.1371\/journal.pmed.1001378"},{"key":"10.3238\/arztebl.2013.0575_ref19","unstructured":"Dickersin K: Reporting and other biases in studies of Neurontin for migraine, psychiatric\/bipolar disorders, nociceptive pain, and neuropathic pain: www.prescriptionaccess.org\/docs\/neurontin_exh_O.pdf. 10 August 2008. Last accessed on 6 November 2012."},{"key":"10.3238\/arztebl.2013.0575_ref20","doi-asserted-by":"crossref","unstructured":"Nast A, Kopp IB, Augustin M, et al.: S3-Leitlinie zur Therapie der Psoriasis vulgaris. J Dtsch Dermatol Ges 2006; 4 Suppl 2: 1\u2013126.","DOI":"10.1111\/j.1610-0387.2006.06172.x"},{"key":"10.3238\/arztebl.2013.0575_ref21","unstructured":"D\u00fcnnweber C: Einfluss pharmazeutischer Unternehmen auf die Empfehlung \u00e4rztlicher Leitlinien. Berlin School of Public Health an der Charit\u00e9, Weiterbildender Masterstudiengang \u201eMaster of Public Health\u201c. Master\u2019s thesis submitted on 30 September 2010."},{"key":"10.3238\/arztebl.2013.0575_ref22","doi-asserted-by":"crossref","unstructured":"Cosgrove L, Bursztajn HJ, Krimsky S, Anaya M, Walker J: Conflicts of interest and disclosure in the American Psychiatric Association\u2019s Clinical Practice Guidelines. Psychother Psychosom 2009; 78: 228\u201332.","DOI":"10.1159\/000214444"},{"key":"10.3238\/arztebl.2013.0575_ref23","unstructured":"Therapie der Migr\u00e4ne. In: Kommission \u201eLeitlinien der Deutschen Gesellschaft f\u00fcr Neurologie\u201c (ed): Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. 4th edition, Stuttgart: Georg Thieme Verlag, 2008; 579\u201395."},{"key":"10.3238\/arztebl.2013.0575_ref24","unstructured":"Therapie neuropathischer Schmerzen. In: Kommission \u201eLeitlinien der Deutschen Gesellschaft f\u00fcr Neurologie\u201c (ed): Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. 4th edition, Stuttgart: Georg Thieme Verlag, 2008; 630\u20139."},{"key":"10.3238\/arztebl.2013.0575_ref25","unstructured":"Deutsche Interdisziplin\u00e4re Vereinigung f\u00fcr Schmerztherapie (DIVS) e.V.: S3-Leitlinie \u201eBehandlung akuter perioperativer und posttraumatischer Schmerzen\u201c: www.awmf.org\/uploads\/tx_ szleitlinien\/041\u2013001_S3_Behandlung_akuter_perioperativer_ und_posttraumatischer_Schmerzen_aktualisierte_Fassung_ 04\u20132009_05\u20132011.pdf. AWMF-Register Nr. 041\/001;Status: 21 Mai 2007, modified on 20 April 2009. Last accessed on 6 November 2012."},{"key":"10.3238\/arztebl.2013.0575_ref26","doi-asserted-by":"crossref","unstructured":"Wiffen PJ, McQuay HJ, Edwards JE, Moore RA: Gabapentin for acute and chronic pain. Cochrane Database Syst Rev 2005; Issue 3: CD005452.","DOI":"10.1002\/14651858.CD005452"},{"key":"10.3238\/arztebl.2013.0575_ref27","unstructured":"National Institute for Health and Clinical Excellence: Etanercept and efalizumab for the treatment of adults with psoriasis: www.nice.org.uk\/nicemedia\/live\/11580\/33376\/33376.pdf. NICE technology appraisal guidance 103. Issue date: July 2006, re-issued: December 2009. Last accessed on 6 November 2012."},{"key":"10.3238\/arztebl.2013.0575_ref28","unstructured":"Woolacott N, Hawkins N, Mason A, et al.: Efalizumab and Etanercept for the Treatment of Psoriasis: www.nice.org.uk\/nicemedia\/live\/11579\/33369\/33369.pdf. CRD\/CHE Technology Assessment Group; Technology Assessment Report commissioned by the HTA Programme on behalf of The National Institute for Clinical Excellence, February 2005. Last accessed on 6 November 2012."},{"key":"10.3238\/arztebl.2013.0575_ref29","unstructured":"Baron R: Diagnostik und Therapie neuropathischer Schmerzen: Dtsch Arztebl 2006; 103: A-2720\u201330."},{"key":"10.3238\/arztebl.2013.0575_ref30","unstructured":"Diagnostik und Therapie neuropathischer Schmerzen. In: Kommission \u201eLeitlinien der Deutschen Gesellschaft f\u00fcr Neurologie\u201c (ed): Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. 3rd edition, Stuttgart: Georg Thieme Verlag, 2005; 531\u201344."},{"key":"10.3238\/arztebl.2013.0575_ref31","doi-asserted-by":"crossref","unstructured":"Tan JK, Wolfe BJ, Bulatovic R, Jones EB, Lo AY: Critical appraisal of quality of clinical practice guidelines for treatment of psoriasis vulgaris, 2006\u20132009. J Invest Dermatol 2010; 130: 2389\u201395.","DOI":"10.1038\/jid.2010.164"},{"key":"10.3238\/arztebl.2013.0575_ref32","unstructured":"Hennekens CH, Buring JE: Descriptive Studies. In: Mayrent SL (ed): Epidemiology in Medicine. Bosten, Toronto: Little, Brown and Company, 1987; 101\u201331."},{"key":"10.3238\/arztebl.2013.0575_ref33","doi-asserted-by":"crossref","unstructured":"Camilleri M, Cortese DA: Managing conflict of interest in clinical practice. Mayo Clin Proc 2007; 82: 607\u201314.","DOI":"10.4065\/82.5.607"},{"key":"10.3238\/arztebl.2013.0575_ref34","unstructured":"Lewis SZ: Building a better guideline: overcoming challenges and establishing transparency: www.guidelines.gov\/expert\/expert-commentary.aspx?id=16448. National Guideline Clearinghouse\u2122 (NGC) Expert Commentary, April 2008. Last accessed on 6 November 2012."},{"key":"10.3238\/arztebl.2013.0575_ref35","doi-asserted-by":"crossref","unstructured":"Sch\u00fcnemann HJ, Woodhead M, Anzueto A, Buist S, Macnee W, Rabe KF, et al.: A vision statement on guideline development for respiratory disease: the example of COPD. Lancet 2009; 373: 774\u20139.","DOI":"10.1016\/S0140-6736(08)61347-1"},{"key":"10.3238\/arztebl.2013.0575_ref36","doi-asserted-by":"crossref","unstructured":"Sniderman AD, Furberg CD: Why guideline-making requires reform. JAMA 2009; 301: 429\u201331.","DOI":"10.1001\/jama.2009.15"},{"key":"10.3238\/arztebl.2013.0575_ref37","doi-asserted-by":"crossref","unstructured":"Rothman DJ, McDonald WJ, Berkowitz CD, Chimonas SC, DeAngelis CD, Hale RW, et al.: Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA 2009; 301: 1367\u201372.","DOI":"10.1001\/jama.2009.407"},{"key":"10.3238\/arztebl.2013.0575_ref38","doi-asserted-by":"crossref","unstructured":"Steinbrook R: Controlling conflict of interest \u2013 proposals from the Institute of Medicine. N Engl J Med 2009; 360: 2160\u20133.","DOI":"10.1056\/NEJMp0810200"},{"key":"10.3238\/arztebl.2013.0575_ref39","unstructured":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (AWMF): Empfehlungen der AWMF zum Umgang mit Interessenkonflikten bei Fachgesellschaften: www.awmf.org\/fileadmin\/user_upload\/Leitlinien\/Werkzeuge\/empf-coi.pdf. Erarbeitet von einer Ad-hoc-Kommission der AWMF und verabschiedet vom Pr\u00e4sidium der AWMF am 23. April 2010. Last accessed on 6 November 2012."},{"key":"10.3238\/arztebl.2013.0575_ref40","unstructured":"St\u00f6hr K: Leitlinien, Richtlinien und \u00e4rztliche Haftung. In: M\u00fcller GOE, Stein T (eds): Festschrift f\u00fcr G\u00fcnther Hirsch. M\u00fcnchen: Verlag C. H. Beck 2011; 431\u201341."},{"key":"10.3238\/arztebl.2013.0575_ref41","doi-asserted-by":"crossref","unstructured":"Bekelman JE, Li Y, Gross CP: Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 2003; 289: 454\u201365.","DOI":"10.1001\/jama.289.4.454"},{"key":"10.3238\/arztebl.2013.0575_ref42","doi-asserted-by":"crossref","unstructured":"Bero LA, Rennie D: Influences on the quality of published drug studies. Int J Technol Assess Health Care 1996; 12: 209\u201337.","DOI":"10.1017\/S0266462300009582"},{"key":"10.3238\/arztebl.2013.0575_ref43","doi-asserted-by":"crossref","unstructured":"Lexchin J, Bero LA, Djulbegovic B, Clark O: Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003; 326: 1167\u201370.","DOI":"10.1136\/bmj.326.7400.1167"},{"key":"10.3238\/arztebl.2013.0575_ref44","unstructured":"Arzneimittelkommission der deutschen \u00c4rzteschaft: Der Einfluss pharmazeutischer Unternehmen auf \u00e4rztliche Leitlinien \u2013 Expertise: www.akdae.de\/Stellungnahmen\/Weitere\/20120123.pdf. Berlin, Januar 2012. Zuletzt gepr\u00fcft: 6. November 2012."},{"key":"10.3238\/arztebl.2013.0575_ref45","doi-asserted-by":"crossref","unstructured":"Buchan HA, Currie KC, Lourey EJ, Duggan GR: Australian clinical practice guidelines \u2013 a national study. Med J Aust 2010; 192: 490\u20134.","DOI":"10.5694\/j.1326-5377.2010.tb03604.x"},{"key":"10.3238\/arztebl.2013.0575_ref46","doi-asserted-by":"crossref","unstructured":"Papanikolaou GN, Baltogianni MS, Contopoulos-Ioannidis DG, Haidich AB, Giannakakis IA, Ioannidis JP: Reporting of conflicts of interest in guidelines of preventive and therapeutic interventions. BMC Med Res Methodol 2001; 1: 3.","DOI":"10.1186\/1471-2288-1-3"},{"key":"10.3238\/arztebl.2013.0575_ref47","doi-asserted-by":"crossref","unstructured":"Cosgrove L, Bursztajn HJ, Krimsky S: Developing unbiased diagnostic and treatment guidelines in psychiatry. N Engl J Med 2009; 360: 2035\u20136.","DOI":"10.1056\/NEJMc0810237"},{"key":"10.3238\/arztebl.2013.0575_ref48","doi-asserted-by":"crossref","unstructured":"Choudhry NK, Stelfox HT, Detsky AS: Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 2002; 287: 612\u20137.","DOI":"10.1001\/jama.287.5.612"},{"key":"10.3238\/arztebl.2013.0575_ref49","doi-asserted-by":"crossref","unstructured":"Cosgrove L, Krimsky S, Vijayaraghavan M, Schneider L: Financial ties between DSM-IV panel members and the pharmaceutical industry. Psychother Psychosom 2006; 75: 154\u201360.","DOI":"10.1159\/000091772"},{"key":"10.3238\/arztebl.2013.0575_ref50","doi-asserted-by":"crossref","unstructured":"Holloway RG, Mooney CJ, Getchius TS, Edlund WS, Miyasaki JO: Invited article: conflicts of interest for authors of American Academy of Neurology clinical practice guidelines. Neurology 2008; 71: 57\u201363.","DOI":"10.1212\/01.wnl.0000316319.19159.c3"},{"key":"10.3238\/arztebl.2013.0575_ref51","doi-asserted-by":"crossref","unstructured":"Mendelson TB, Meltzer M, Campbell EG, Caplan AL, Kirkpatrick JN: Conflicts of interest in cardiovascular clinical practice guidelines. Arch Intern Med 2011; 171: 577\u201384.","DOI":"10.1001\/archinternmed.2011.96"},{"key":"10.3238\/arztebl.2013.0575_ref52","doi-asserted-by":"crossref","unstructured":"Neuman J, Korenstein D, Ross JS, Keyhani S: Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: cross sectional study. BMJ 2011; 343: d5621.","DOI":"10.1136\/bmj.d5621"},{"key":"10.3238\/arztebl.2013.0575_ref53","doi-asserted-by":"crossref","unstructured":"Taylor R, Giles J: Cash interests taint drug advice. Nature 2005; 437: 1070\u20131.","DOI":"10.1038\/4371070a"},{"key":"10.3238\/arztebl.2013.0575_ref54","doi-asserted-by":"crossref","unstructured":"Kung J, Miller RR, Mackowiak PA: Failure of clinical practice guidelines to meet Institute of Medicine standards: two more decades of little, if any, progress. Arch Intern Med 2012; 172: 1628\u201333.","DOI":"10.1001\/2013.jamainternmed.56"},{"key":"10.3238\/arztebl.2013.0575_ref55","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D (eds): Arzneiverordnungs-Report 2010. Berlin, Heidelberg: Springer Medizin Verlag, 2010.","DOI":"10.1007\/978-3-642-13380-0"},{"key":"10.3238\/arztebl.2013.0575_ref56","unstructured":"Pfizer Pharma GmbH: Neurontin\u00ae 100\/300\/400 mg Hartkapseln. Stand: Juni 2011."},{"key":"10.3238\/arztebl.2013.0575_ref57","unstructured":"FDA: FDA Approved Drug Products: Neurontin: \/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search. Search_Drug_Name. FDA Center for Drug Evaluation and Research, Office of Communications, Division of Information Services. Last accessed on 6 November 2012."},{"key":"10.3238\/arztebl.2013.0575_ref58","unstructured":"Abramson J: Expert report of John Abramson, MD.: http:\/\/dida.library.ucsf.edu\/pdf\/oxx18v10. Neurontin Marketing and Sales Practices Litigation, MDL #1629, Docket #04\u201310981; 11 August 2008. Last accessed on 6 November 2012."},{"key":"10.3238\/arztebl.2013.0575_ref59","unstructured":"Claes C, Kulp W, Greiner W, Graf von der Schulenburg J-M, Werfel T: Deutsches Institut f\u00fcr Medizinische Dokumentation und Information (DIMDI) (eds): Therapie der mittelschweren und schweren Psoriasis. Bd. 34, Schriftenreihe Health Technology Assessment (HTA). K\u00f6ln: DIMDI, 2006."},{"key":"10.3238\/arztebl.2013.0575_ref60","unstructured":"IMP24011. Phase III, randomised, double blind, placebo-controlled, multicentre study evaluating 12 weeks subcutaneous therapy with Genentech efalizumab in patients with moderate to severe psoriasis who are candidates for systemic therapy. In: Clinical and cost effectiveness of efalizumab (Raptiva) for moderate to severe psoriasis. [Industry submission]. Feltham: Serono Ltd., 2004."},{"key":"10.3238\/arztebl.2013.0575_ref61","unstructured":"ACD2600g. Phase IIIb, randomised, double-blind, parallel group, placebocontrolled, multicentre study evaluating 12 weeks therapy with subcutaneously administered Genentech efalizumab in adults with moderate to severe psoriasis who are candidates for systemic therapy. In: Clinical and cost effectiveness of efalizumab (Raptiva) for moderate to severe psoriasis. [Industry submission]. Feltham: Serono Ltd., 2004."},{"key":"10.3238\/arztebl.2013.0575_ref62","unstructured":"ACD2058g. Phase III, randomised double blind placebo-controlled study evaluating 12 weeks of therapy with XOMA1 efalizumab administered subcutaneously (SC), followed by either continued treatment for an additional 12 weeks or re-treatment for 12 weeks following a relapse. In: Clinical and cost effectiveness of efalizumab (Raptiva) for moderate to severe psoriasis. [Industry submission]. Feltham: Serono Ltd., 2004."},{"key":"10.3238\/arztebl.2013.0575_ref63","unstructured":"Hofelich V: Ergebnisse zur Evaluation der S3-Leitlinie zur Therapie der Psoriasis vulgaris in Deutschland: www.diss.fu-berlin.de\/diss\/servlets\/MCRFileNodeServlet\/FUDISS_derivate_000000006571\/ Promotion_online.pdf. Dissertation; Klinik f\u00fcr Dermatologie, Venerologie und Allergologie der Medizinischen Fakult\u00e4t Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Januar 2010. Last accessed on 6 November 2012."},{"key":"10.3238\/arztebl.2013.0575_ref64","unstructured":"Serono Europe Ltd.: Fachinformation \u201eRaptiva\u00ae\u201c. Status: September 2004."},{"key":"10.3238\/arztebl.2013.0575_ref65","unstructured":"EMA: Public statement on Raptiva (efalizumab): Withdrawel of the marketing authorisation in the European Union: www.ema.europa.eu\/docs\/en_GB\/document_library\/Public_statement\/ 2009\/11\/WC500009129.pdf. London, 3 August 2009;Doc. Ref. EMEA\/487107\/2009. Last accessed on 6 November 2012."},{"key":"10.3238\/arztebl.2013.0575_ref66","doi-asserted-by":"crossref","unstructured":"Mathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N, et al.: Efficacy of gabapentin in migraine prophylaxis. Headache 2001; 41: 119\u201328.","DOI":"10.1046\/j.1526-4610.2001.111006119.x"},{"key":"10.3238\/arztebl.2013.0575_ref67","doi-asserted-by":"crossref","unstructured":"Serpell MG: Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain 2002; 99: 557\u201366.","DOI":"10.1016\/S0304-3959(02)00255-5"},{"key":"10.3238\/arztebl.2013.0575_ref68","doi-asserted-by":"crossref","unstructured":"Backonja M, Beydoun A, Edwards KR, et al.: Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998; 280: 1831\u20136.","DOI":"10.1001\/jama.280.21.1831"},{"key":"10.3238\/arztebl.2013.0575_ref69","doi-asserted-by":"crossref","unstructured":"Caraceni A, Zecca E, Bonezzi C, et al.: Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol 2004; 22: 2909\u201317.","DOI":"10.1200\/JCO.2004.08.141"},{"key":"10.3238\/arztebl.2013.0575_ref70","doi-asserted-by":"crossref","unstructured":"Dallocchio C, Buffa C, Mazzarello P, Chiroli S: Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study. J Pain Symptom Manage 2000; 20: 280\u20135.","DOI":"10.1016\/S0885-3924(00)00181-0"},{"key":"10.3238\/arztebl.2013.0575_ref71","doi-asserted-by":"crossref","unstructured":"Gorson KC, Schott C, Herman R, Ropper AH, Rand WM: Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. J Neurol Neurosurg Psychiatry 1999; 66: 251\u20132.","DOI":"10.1136\/jnnp.66.2.251"},{"key":"10.3238\/arztebl.2013.0575_ref72","doi-asserted-by":"crossref","unstructured":"Wiffen PJ, McQuay HJ, Edwards J, Moore RA: WITHDRAWN: Gabapentin for acute and chronic pain. Cochrane Database Syst Rev 2011; Issue 3: CD005452.","DOI":"10.1002\/14651858.CD005452.pub2"},{"key":"10.3238\/arztebl.2013.0575_ref73","unstructured":"Gottlieb AB, Gordon KB, Lebwohl MG, et al.: Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol 2004; 3: 614\u201324."},{"key":"10.3238\/arztebl.2013.0575_ref74","doi-asserted-by":"crossref","unstructured":"Leonardi CL, Papp KA, Gordon KB, et al.: Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 2005; 52: 425\u201333.","DOI":"10.1016\/j.jaad.2004.09.029"},{"key":"10.3238\/arztebl.2013.0575_ref75","doi-asserted-by":"crossref","unstructured":"Gordon KB, Papp KA, Hamilton TK, et al.: Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003; 290: 3073\u201380.","DOI":"10.1001\/jama.290.23.3073"},{"key":"10.3238\/arztebl.2013.0575_ref76","unstructured":"Menter A, Kosinski M, Bresnahan BW, Papp KA, Ware JE Jr.: Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis. J Drugs Dermatol 2004; 3: 27\u201338."},{"key":"10.3238\/arztebl.2013.0575_ref77","doi-asserted-by":"crossref","unstructured":"Lebwohl M, Tyring SK, Hamilton TK, et al.: A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349: 2004\u201313.","DOI":"10.1056\/NEJMoa030002"},{"key":"10.3238\/arztebl.2013.0575_ref78","doi-asserted-by":"crossref","unstructured":"Menter A, Gordon K, Carey W, et al.: Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005; 141: 31\u20138.","DOI":"10.1001\/archderm.141.1.31"},{"key":"10.3238\/arztebl.2013.0575_ref79","doi-asserted-by":"crossref","unstructured":"Papp K, Bissonnette R, Krueger JG, et al.: The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 2001; 45: 665\u201374.","DOI":"10.1067\/mjd.2001.117850"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2013.0575","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T08:59:23Z","timestamp":1638781163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2013.0575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,2]]},"references-count":79,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2013.0575","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718122773.793484369","asserted-by":"object"}]},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,2]]}}}